BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment

Zacks
Öffnen unter Zacks
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the U.S. commercial launch of the BD Liverty TIPS Stent Graft, a next-generation transjugular intrahepatic portosystemic shunt (TIPS) system designed to support more personalized treatment for patients with portal hypertension. The system provides physicians with greater flexibility, deployment accuracy and control to tailor procedures based on individual patient anatomy, disease progression and clinical goals.

Per management, the Liverty TIPS Stent Graft was developed to give physicians greater flexibility during TIPS procedures. Its extended stent lengths and adjustable diameter options are designed to help clinicians make real-time treatment decisions based on individual patient needs.

BDX Stock Trend Following the News

Year to date, the stock has gained 2% compared with the industry’s 13% growth and the S&P 500’s 9.3% rise.

The U.S. launch of Liverty could strengthen BD's position in the interventional vascular market by expanding its range of specialized treatment solutions. Offering a more adaptable TIPS platform may help BD attract additional physician interest and support product adoption across hospitals and interventional care centers. The launch also provides another opportunity for the company to leverage its clinical expertise and broaden its presence in specialized vascular procedures.

BDX currently has a market capitalization of $54.52 billion.

Zacks Investment Research
Image Source: Zacks Investment Research

More on the Liverty TIPS Stent Graft

Portal hypertension occurs when blood pressure increases in the portal vein system, potentially leading to serious complications such as internal bleeding and fluid accumulation in the abdomen. TIPS is a minimally invasive procedure that creates a new pathway for blood flow through the liver to relieve this pressure. It is commonly used to manage complications such as variceal bleeding and refractory ascites.

The Liverty TIPS Stent Graft is designed to accommodate varying patient requirements through an expandable diameter ranging from 6 to 10 millimeters and covered stent lengths of 4 to 10 centimeters, the longest commercially available. Its fully sheathed, tri-axial delivery system is intended to provide deployment control and accuracy. Radiopaque markers support visualization and placement under fluoroscopy, while the delivery system enables sheathless tracking through the liver parenchyma.

The U.S. launch is supported by six-month interim results from the prospective, multicenter ARCH clinical study, which enrolled 177 patients. The study is the first and only IDE study to provide clinical data on small-diameter (6-7 mm) TIPS. The system also enters the U.S. market with established clinical and physician experience in Europe.

With the commercial introduction of Liverty, BD continues to expand its interventional portfolio and provide physicians with additional options for managing complications associated with portal hypertension.

Industry Prospects Favoring the Market

According to Future Market Insights, the global portal hypertension management market is estimated to be valued at $3.5 billion in 2026 and is expected to witness a CAGR of 4.8% through 2036.

Factors such as the rising prevalence of chronic liver diseases and cirrhosis, increasing demand for treatments for variceal bleeding and other complications, growing adoption of minimally invasive procedures like TIPS and expanding interventional radiology capabilities at hepatology centers are expected to drive market growth.

Other News

BD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.

Becton, Dickinson and Company Price

Becton, Dickinson and Company Price

Becton, Dickinson and Company price | Becton, Dickinson and Company Quote

BDX’s Zacks Rank & Other Key Picks

Currently, BDX carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are OPKO Health OPK, Intuitive Surgical ISRG and Globus Medical GMED.

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.

Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
OPKO Health, Inc. (OPK): Free Stock Analysis Report
 
Globus Medical, Inc. (GMED): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research